Myopia and Presbyopia Treatment Market Report 2026

The myopia and presbyopia treatment market size has grown strongly in recent years. It will grow from $22.63 billion in 2025 to $24.56 billion in 2026 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to increase in aging population, widespread adoption of corrective lenses, rise in screen-induced myopia, early developments in refractive surgery, limited awareness of preventive eye care.

The myopia and presbyopia treatment market size is expected to see strong growth in the next few years. It will grow to $33.57 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to growing demand for advanced surgical solutions, increasing adoption of presbyopia-correcting lenses, rising use of pharmacological treatments, technological innovations in eye care diagnostics, expansion of preventive screening programs. Major trends in the forecast period include increasing adoption of multifocal and advanced contact lenses, rising demand for laser and refractive surgical procedures, growing preference for orthokeratology (ortho-k) in myopia control, higher utilization of pharmacological eye drops for presbyopia, expansion of early vision screening and preventive care programs.

The rising incidence of vision impairment is expected to propel the growth of the myopia and presbyopia treatment market going forward. Vision impairment refers to a condition in which an individual's ability to see and interpret visual information is significantly reduced, causing difficulty in perceiving and understanding their environment. The increasing prevalence of vision impairment drives the development of treatments for myopia and presbyopia, encouraging innovation, investment, improved access to therapies, and better outcomes for patients. For instance, in August 2023, the World Health Organization (WHO), a Switzerland-based United Nations agency, reported that approximately 2.2 billion people globally experience near- or distance-vision impairment, including 1 billion cases that are preventable or untreated. Refractive errors and cataracts are the leading causes of vision loss, yet only 36% of individuals with refractive-error-related distance impairment and 17% of those with cataract-related impairment receive proper care. Therefore, the rising incidence of vision impairment is driving the growth of the myopia and presbyopia treatment market.

Major companies in the myopia and presbyopia treatment market are focusing on innovative solutions, such as myopia-combating sun spectacle lenses, to expand their customer base and increase revenue. Myopia-combating sun spectacle lenses are eyeglass lenses designed to slow the progression of myopia, or near-sightedness, when worn outdoors in bright sunlight. For example, in May 2023, HOYA, a Thailand-based optical technology company, launched MiYOSMART sun spectacle lenses for children. The lenses use DIMS Technology (Defocus Incorporated Multiple Segments), developed in collaboration with the Hong Kong Polytechnic University, which creates simultaneous defocus on the retina: one plane provides single vision, while another plane generates myopic defocus through +3.50D defocus lenslets. Two specialized lens options - photochromic MiYOSMART Chameleon and polarized MiYOSMART Sunbird - protect children from intense sunlight while slowing myopia progression.

In January 2024, Eyenovia Inc., a US-based ophthalmic pharmaceutical technology company, acquired the development and commercialization rights of MicroPine from Bausch + Lomb Ireland Limited for an undisclosed amount. The acquisition aims to accelerate the commercialization of advanced ophthalmic products targeting pediatric progressive myopia, thereby expanding Eyenovia’s late-stage pipeline and addressing a significant unmet medical need in the U.S. and Canada. Bausch + Lomb Ireland Limited is an Ireland-based eye health company focused on developing MicroPine for myopia treatment.

Major companies operating in the myopia and presbyopia treatment market are ALCON Inc., Bausch & Lomb Incorporated, Carl Zeiss AG, Essilor Ltd., Johnson & Johnson Vision Inc., Nidek Corporation, Topcon Corporation, Zimmer Ophthalmic Systems AG, AbbVie Inc., Orasis Pharmaceuticals Ltd., The Cooper Companies Inc., Staar Surgical Co., Eyenovia Inc., Allergan PLC, Hoya Corporation, Menicon Co. Ltd., CooperVision Inc., Visioneering Technologies Inc., AcuFocus Inc., Ocular Therapeutix Inc., SightGlass Vision Inc., Presbia PLC, LensGen Inc., RxSight Inc., Perfect Lens LLC.

North America was the largest region in the myopia and presbyopia treatment market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myopia and presbyopia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the myopia and presbyopia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have disrupted the myopia and presbyopia treatment market by raising the prices of imported lenses, intraocular implants, surgical devices, and diagnostic equipment. The most affected segments include refractive surgery, prescription lenses, and contact lenses, particularly in Asia-Pacific and Europe where cross-border trade in optical components is high. Higher import duties have increased treatment costs and reduced affordability for patients in emerging economies. On the positive side, tariffs are stimulating local manufacturing of lenses and ophthalmic devices, improving domestic supply resilience.

The myopia and presbyopia treatment market research report is one of a series of new reports that provides myopia and presbyopia treatment market statistics, including myopia and presbyopia treatment industry global market size, regional shares, competitors with a myopia and presbyopia treatment market share, detailed myopia and presbyopia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the myopia and presbyopia treatment industry. This myopia and presbyopia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Myopia and presbyopia treatment refers to procedures and therapies aimed at correcting and improving vision affected by myopia and presbyopia in both adults and children. The primary goal of these treatments is to identify underlying vision problems, reduce the risk of eye injury, prevent ocular symptoms, and enable early detection of eye disorders.

The main conditions addressed in myopia and presbyopia treatment are myopia and presbyopia. Myopia is a condition where visual images focus in front of the retina, resulting in reduced ability to see distant objects clearly. Treatments for myopia include corrective methods, surgical procedures, and medications, while presbyopia treatments involve prescription lenses, contact lenses, intraocular lenses, and refractive surgery. These interventions are used to manage vision problems in both adult and pediatric populations.

The myopia and presbyopia treatment market includes revenues earned by entities by performing refractive surgery, lens implants, bifocal surgery services and providing eyesight management treatment. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.